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Post-acute delivery of erythropoietin induces stroke recovery by
promoting perilesional tissue remodelling and contralesional
pyramidal tract plasticity
Abstract
The promotion of post-ischaemic motor recovery remains a major challenge in clinical neurology.
Recently, plasticity-promoting effects have been described for the growth factor erythropoietin in
animal models of neurodegenerative diseases. To elucidate erythropoietin's effects in the post-acute
ischaemic brain, we examined how this growth factor influences functional neurological recovery,
perilesional tissue remodelling and axonal sprouting of the corticorubral and corticobulbar tracts, when
administered intra-cerebroventricularly starting 3 days after 30 min of middle cerebral artery occlusion.
Erythropoietin administered at 10 IU/day (but not at 1 IU/day), increased grip strength of the
contralesional paretic forelimb and improved motor coordination without influencing spontaneous
locomotor activity and exploration behaviour. Neurological recovery by erythropoietin was associated
with structural remodelling of ischaemic brain tissue, reflected by enhanced neuronal survival, increased
angiogenesis and decreased reactive astrogliosis that resulted in reduced scar formation. Enhanced
axonal sprouting from the ipsilesional pyramidal tract into the brainstem was observed in vehicle-treated
ischaemic compared with non-ischaemic animals, as shown by injection of dextran amines into both
motor cortices. Despite successful remodelling of the perilesional tissue, erythropoietin enhanced axonal
sprouting of the contralesional, but not ipsilesional pyramidal tract at the level of the red and facial
nuclei. Moreover, molecular biological and histochemical studies revealed broad anti-inflammatory
effects of erythropoietin in both hemispheres together with expression changes of plasticity-related
molecules that facilitated contralesional axonal growth. Our study establishes a plasticity-promoting
effect of erythropoietin after stroke, indicating that erythropoietin acts via recruitment of contralesional
rather than of ipsilesional pyramidal tract projections.
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Summary: The promotion of post-ischemic motor recovery remains a major 
challenge in clinical neurology. Recently, plasticity-promoting effects have been 
described for the growth factor erythropoietin (Epo) in animal models of 
neurodegenerative diseases. To elucidate Epo’s effects in the post-acute ischemic 
brain, we examined how this growth factor influences functional neurological 
recovery, perilesional tissue remodeling and axonal sprouting of the corticorubral and 
corticobulbar tracts, when administered intracerebroventricularly starting three days 
after 30 min middle cerebral artery occlusion. Epo administered at 10 but not 1 
I.U./day increased grip strength of the contralesional paretic forelimb and improved 
motor coordination, without influencing spontaneous locomotor activity and 
exploration behavior. Neurological recovery by Epo was associated with structural 
remodeling of ischemic brain tissue, reflected by enhanced neuronal survival, 
increased angiogenesis and decreased reactive astrogliosis turning into reduced scar 
formation. Enhanced axonal sprouting from the ipsilesional pyramidal tract into the 
brainstem was observed in vehicle-treated ischemic compared with non-ischemic 
animals, as shown by dextran amines that were injected into both motor cortices. 
Despite successful remodeling of the perilesional tissue, Epo enhanced axonal 
sprouting of the contralesional, but not ipsilesional pyramidal tract at the level of the 
red and facial nuclei. Moreover, molecular biological and histochemical studies 
revealed broad anti-inflammatory effects of Epo in both hemispheres together with 
expression changes of plasticity-related molecules that facilitated contralesional 
axonal growth. Our study establishes a plasticity-promoting effect of Epo after stroke, 
indicating that Epo acts via recruitment of contralesional rather than of ipsilesional 
pyramidal tract projections. 
Key-words: Focal cerebral ischemia; hematopoietic growth factor; axonal growth; 
inflammation. 
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Introduction 
Stroke remains the leading cause of serious motor disabilities in adults (Bonita et al., 
1994). Whereas initially hemiparesis affects 80-90% of patients, later on still 45-60% 
exhibit motor deficits in the post-acute stroke phase (Dobkin, 1996). Thus, 
neurological recovery is limited. Post-ischemic endogenous responses of the central 
nervous system go in line with an enhanced responsiveness to rehabilitative 
(Biernaskie et al., 2004) and plasticity-promoting (Papadopoulus et al., 2002; 
Seymour et al., 2005) treatments, opening a time window in which ontogenetic brain 
repair mechanisms may successfully be reactivated (Cramer and Chopp, 2000; 
Buchli and Schwab, 2005). 
Stroke recovery is associated with reorganisation of neuronal circuits both at the 
cortical and subcortical level. Latent networks are unmasked or strengthened, 
assuring the interaction between perilesional and distant brain areas. In the ischemic 
boundary zone, a cascade of events including angiogenesis (Chen et al., 2008), 
inhibition of astrogliosis (Li et al., 2005) and anti-inflammation (Bacigaluppi et al., 
2009) are contributing to the remodeling of brain tissue. Beside this, a series of 
events set the stage for brain reorganization in th  intact hemisphere, such as 
increased angiogenesis (Ding et al., 2008) and axonal sprouting (Papadopoulus et 
al., 2002; Wiessner et al., 2003). So far, previous studies examined ipsilesional and 
contralesional recovery processes independent from each other. There are no 
studies evaluating how both processes are coordinated. 
Recruitment of contralesional brain areas correlated with a better recovery from 
stroke in animal studies (Papadopoulus et al., 2002; Wiessner et al., 2003). By 
administering anterograde tract tracers into the contralesional motor cortex, these 
authors suggested that contralateral projections may be recruited by plasticity-
promoting therapies, underlining the relevance of contralesional reorganisation in 
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neurological recovery. However, models of permanent focal cerebral ischemia were 
used in the latter studies, in which motor cortex tissue was destroyed. Brain plasticity 
ipsilateral to the stroke was not systematically assessed in these studies. 
Beside animal studies, evidence from positron emission tomography (PET), 
functional magnetic resonance imaging (fMRI), transcranial magnetic stimulation 
(TMS) and magnetoencephalography (MEG) studies also supported the relevance of 
contralesional brain plasticity for human stroke recovery (Cramer et al, 1997; Musso 
et al., 1999; Gerloff et al., 2006; van der Zijden et al., 2008). However, implications of 
contralesional activation were difficult to interpret as activation patterns in humans 
are strongly influenced by severity and inhomogeneity of strokes. Whether the 
promotion of functional neurological recovery with growth factors influences 
contralesional reorganization processes was not described. 
The identification of erythropoietin (Epo) and its receptor in neurons, astrocytes and 
cerebral microvascular endothelial cells and its sustained production in the hypoxic-
ischemic central nervous system (CNS) (Marti et al., 1996; Bernaudin et al., 2000; 
Grimm et al., 2005) has established Epo as a potent survival-promoting factor that 
inhibits neuronal ischemic injury (Tan et al., 1992; Kilic et al., 2005a; Li et al., 2007) 
and prevents infarction (Siren et al., 2001; Kilic et al., 2005a; Li et al., 2007) by 
modulating distinct cytosolic signaling pathways (Siren et al., 2001; Kilic et al., 2005a, 
2005b). In cell culture, Epo also potently induced endothelial cell proliferation 
(Bernaudin et al., 1999) and capillary tube formation (Wang et al., 2004), thus 
pointing towards a role of this growth factor also in angiogenesis (Li et al., 2007). 
Because Epo is already clinically used with little side effects (e.g., Hudson and 
Sameri, 2002), experimental studies rapidly led to clinical trials, in which the growth 
factor was acutely administered to stroke patients. In a first proof-of-principle study, 
Epo significantly enhanced neurological outcome and reduced ischemic injury, 
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indicating that the growth factor is both safe and beneficial (Ehrenreich et al., 2002). 
In a subsequent larger study including 522 patients, in which Epo was infused 
intravenously after acute ischemic stroke both in patients with (60%) and without 
(40%) thrombolysis, Epo did not improve clinical outcome, but unexpectedly 
increased the risk of bleeding, brain edema and thrombembolic events in 
thrombolyzed patients (Ehrenreich et al., 2009). Explorative analysis in patients not 
receiving thrombolytics reproduced some of the earlier findings, indicating that Epo 
alone may nonetheless be efficacious (Ehrenreich et al., 2009). Due to the expansion 
of the therapeutic window for intravenous thrombolysis to 4.5 hours (Hacke et al., 
2008), unfortunately acute neuroprotection studies with Epo in patients not receiving 
thrombolysis may not be feasible in the near future. 
In addition to its survival-promoting activities, Epo exhibits plasticity-promoting 
actions in models of slowly progressive neurodegeneration. As such, Epo increased 
ventral mesencephalic fibre outgrowth in a rodent model of Parkinson’s disease 
(McLeod et al., 2006) and enhanced axonal sprouting in a model of optic nerve 
transection (King et al., 2007). Recently, Epo was also shown to promote perilesional 
tissue remodeling in a rat model of focal cerebral ischemia (Li et al., 2009). Until now, 
it has remained unknown whether and how the post-acute delivery of Epo after stroke 
influences axonal plasticity processes. We here investigated this issue, using a 
strategy of simultaneous analysis of pyramidal tract sprouting ipsi- and contralateral 
to the stroke in mice, which we combined with a detailed histochemical evaluation of 
perilesional brain remodeling, thus characterizing how endogenous brain responses 
are modulated by Epo. 
 
Materials and Methods 
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Animal groups 
Experiments were performed in accordance to National Institutes of Health 
Guidelines for the Care and Use of Laboratory Animals with local government 
approval (Bezirksregierung Düsseldorf, TSG966/08). Male C57Bl6/j mice (8-10 
weeks; 23-25 g) were submitted to 30 min of left-sided middle cerebral artery 
occlusion (MCAO) (Kilic et al., 2005a, 2006, 2008). At 72 hours post-ischemia, 
animals received implantations of miniosmotic pumps into the left-sided lateral 
ventricle that were randomly filled with 0.9% NaCl (vehicle) or Epo (1 or 10 I.U. / day 
diluted in 0.9% NaCl) and were left in place during the subsequent four weeks (Fig. 
1). 
In addition to animals undergoing MCAO, sham-operated animals were also 
operated, in which vehicle filled pumps were implanted as specified.  
One set of mice was used for studies on functional neurological recovery and for 
analysis of axonal plasticity (n = 10 animals per group; Fig. 1A). For that purpose, 
mice received anterograde tract tracer injections (see below) in both frontal motor 
cortices 42 days after the stroke was induced (Fig. 1A). Ten days later, these animals 
were sacrificed (Fig. 1A). 
Additional male C57Bl6/j mice were also subjected to 30 min MCAO using the same 
protocol, followed by implantation of intraventricular pumps filled with vehicle or Epo 
(10 I.U. / day in 0.9% NaCl) three days later. These animals were sacrificed at 3, 14 
and 30 days (used for reverse transcriptase-polymerase chain reaction [RT-PCR] 
studies) or at 14, 30 or 52 days (used for conventional histochemical studies, 
immunohistochemistry and Western blots) after the stroke (n = 4 animals per group, 
survival time and series) (Fig. 1B, C). For RT-PCR studies, additional sham-operated 
mice (n = 4) and control mice submitted to 30 min MCAO without pump implantation 
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(n = 4) were also operated. The latter sham-operated and untreated mice were 
sacrificed at 3 days post-surgery. 
 
Induction of focal cerebral ischemia 
Animals were anesthetized with 1% isoflurane (30% O2, remainder N2O). Rectal 
temperature was maintained between 36.5 and 37.0°C using a feedback-controlled 
heating system. Cerebral blood flow was analyzed by laser Doppler flow (LDF) 
recordings. Focal cerebral ischemia was induced using an intraluminal filament 
technique (Kilic et al., 2008). Shortly, a midline neck incision was made, and the left 
common and external carotid arteries were isolated and ligated. A microvascular clip 
was temporarily placed on the internal carotid artery. A silicon resin coated nylon 
monofilament was introduced through a small incision into the common carotid artery 
and advanced to the carotid bifurcation for MCAO. Thirty minutes later, reperfusion 
was initiated by monofilament removal. LDF changes were monitored up to 30 min 
after reperfusion onset. In sham-operated animals, a surgical intervention was 
performed, in which the neck was opened and the common carotid artery was 
exposed, but left intact, while LDF recordings were performed. After the surgery, 
wounds were carefully sutured, anaesthesia was discontinued and animals were 
placed back into their cages. Animal drop-outs occurred rarely during and following 
30 min MCAO (<10% of animals) and were related mostly to anaesthesia 
complications or surgery mistakes. 
 
Intraventricular pump implantation 
Three days after surgery animals were reanesthetized with 1% isofluran (30% O2, 
remainder N2O) and cannulae (Brain infusion kit 3, Alzet, Cupertino, CA) linked to 
miniosmotic pumps (Alzet 2004 or 1002; Alzet) filled with 0.9% NaCl or Epo 
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(NeoRecormon, Roche, Basel, Switzerland) (1 or 10 I.U./day in 0.9% NaCl) were 
implanted into the left-sided lateral ventricle through a bur hole (Kilic et al., 2010). 
These pumps administered an infusion volume of 0.25 µl / hour. The pumps were left 
in place up until 30 days post-ischemia (dpi) and then removed. Drop-outs during 
pump implantation were also rare events (<10% of animals) that occurred mostly as 
anaesthesia complications. Thus, such drop-outs did not have significant effects on 
the results of this study. Following pump implantation, no intracerebral bleedings and 
no overt infections were noticed around the needle tracks. Two animals removed 
their pumps before day 30 after ischemia. These animals were not included in the 
data analysis. 
 
Functional neurological tests 
Functional neurological recovery was assessed using a battery of tests at baseline 
and on days 3, 14 and 42 after MCAO.  
Grip strength test. The grip strength test consists of a spring balance coupled with a 
Newtonmeter (Medio-Line Spring Scale, metric, 300g, Pesola AG, Switzerland) that 
is attached to a triangular steel wire, which the animal instinctively grasps. When 
pulled by the tail, the animal exerts force on the steel wire (Kilic et al., 2010). Grip 
strength was evaluated at the right paretic forepaw, the left non-paretic forepaw 
being wrapped with adhesive tape. Grip strength was evaluated five times on 
occasion of each test, for which mean values were calculated. From these data, 
percentage values (post-ischemic vs. pre-ischemic) were computed. Pre-ischemic 
and pre-treatment results did not differ between groups.  
RotaRod test. The RotaRod consists of a rotating drum with a speed accelerating 
from 6 to 40 rpm (Ugo Basile, model 47600, Comerio, Italy), which allows to assess 
motor coordination skills (Kilic et al., 2010). Maximum speed is reached after 245 
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seconds, and the time at which the animal drops off the drum is evaluated (maximum 
testing time: 300 seconds). Measurements were performed five times each on the 
same occasion when grip strength was evaluated. For all five measurements, mean 
values were computed, from which percentage values (post-ischemic vs. pre-
ischemic) were calculated. Pre-ischemic and pre-treatment data did not differ 
between groups.  
Elevated O maze. The elevated O maze consists of a round 5.5 cm wide polyvinyl-
chloride runway with an outer diameter of 46 cm, which is placed 40 cm above the 
floor and which detects spontaneous locomotor behaviour and correlates of fear and 
anxiety (Kilic et al., 2010). Two opposing 90° sectors are protected by 16 cm high 
inner and outer walls made of polyvinyl-chloride (closed sectors). The remaining two 
90° sectors are not protected by walls (open sectors). Animals were released in one 
of the closed sectors and observed for 10 min. The total number of zone entries - as 
correlate of motor activity - and the time spent in the unprotected sector - as correlate 
of exploration behaviour, fear and anxiety - were registered whenever the animal 
moved into a sector with all four paws. Assessments took place at baseline and at 
two and six weeks post-stroke. 
 
Delivery of Cascade Blue-labelled dextran amine (CB) and biotinylated dextran 
amine (BDA) 
The anterograde tract tracer BDA has previously been used to evaluate pyramidal 
tract plasticity contralateral to the stroke in rats submitted to permanent focal cerebral 
ischemia (Wiessner et al., 2003). We here adopted this method to mice, 
administering two different tracers, CB and BDA, in the motor cortex both ipsilateral 
(CB) and contralateral (BDA) to the stroke. For this purpose, cranial bur holes were 
drilled 0.5 mm rostral and 2.5 mm lateral to the bregma, via which deposits of 10% 
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CB or 10% BDA (both 10,000 MW; Molecular Probes, diluted in 0.01 M phosphate-
buffered saline [PBS] at pH 7.2) were placed into the motor cortex by means of 
microsyringe injections six weeks after MCAO. As such, a total volume of 2.1 µl 
tracer was administered to each animal, which was injected in three equal deposits 
located rostrally, medially and caudally of the bur hole inside the motor cortex. For 
this purpose, the syringe was inserted into the brain at angles of 45°, 90° and 135° 
against the midline at a depth of 1.5 mm (Z’Graggen et al., 1998). Tract tracer 
injections did not result in animal drop outs. No macroscopical bleedings and no overt 
infections were observed around the tracer deposits. 
Ten days after the tracer injection, mice were transcardially perfused with 0.1 M PBS 
pH 7.4 containing 100,000 I.U. heparin and 0.25% NaNO2 followed by 4% 
paraformaldehyde in 0.1 M PBS and 5% sucrose. Brains were removed and post-
fixed over-night in 4% paraformaldehyde in 0.1 M PBS and 5% sucrose and 
cryoprotected in increasing concentrations of sucrose (5%, 10% and 30%) over 3 
days. The tissue was then frozen with isopentan and cut into 20 µm and 40 µm thick 
coronal cryostat sections that were used for conventional and tract tracing 
histochemistry. 
 
Immunohistological stainings at the level of ischemic striatum 
For conventional immunohistochemistry, four animals per each therapy group were 
transcardially perfused with 0.9% NaCl at 14, 30 and 52 days after the stroke. Brain 
were frozen on dry ice and cut on a cryostat into 20 µm coronal sections (Kilic et al., 
2010). Brain sections from the level of the bregma (i.e. midstriatum) were fixed in 4% 
PFA in 0.1 M PBS, rinsed, pre-treated for antigen retrieval with 0.01 M citrate buffer 
(pH 5.0), again rinsed and immersed for 1 h in 0.1 M PBS containing 0.3% Triton X-
100 (PBS-T) and 10% normal donkey serum. Brain sections were incubated 
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overnight at 4°C with monoclonal mouse anti-NeuN (MAB377; Chemicon), 
monoclonal rat anti-CD31 (#557355; BD Biosciences), monoclonal mouse anti-GFAP 
Alexa Fluor 555 conjugated (#3656; Cell Signaling), monoclonal rat anti-CD45 
antigen (#550539; BD Pharmingen) and polyclonal rabbit anti-ionized calcium binding 
adaptor protein (Iba)-1 (Wako Chemicals, Neuss, Germany) antibodies (diluted 1:100 
in 0.1 M PBS) that were detected with Cy3 or Cy2 conjugated secondary antibodies 
(Jackson ImmunoResearch, Suffolk, UK). Sections were conterstained with 4’-6-
diamidino-2-phenylindole (DAPI). In some experiments (CD45, Iba1) biotinylated 
secondary antibodies were used that were detected with avidin-biotin kit (Vector 
Laboratories, Burlingame, CA) followed by 3,3’-diaminobenzidine (DAB) (#D4418, 
Sigma, Missouri, USA) staining. Sections were evaluated under a fluorescence 
microscope (Olympus BX 41) connected to a CCD camera (CC12; Olympus). 
Surviving neurons (NeuN+), microvascular profiles (CD31+), reactive astroglia 
(GFAP+), leukocytes (CD45+) and microglia  (Iba1+) were analysed in a blinded way 
by counting numbers of cells or profiles in six defined regions of interests per striatum 
measuring 62,500 µm2, both ipsi- and contralateral to the stroke (Kilic et al., 2005a, 
2006). Two sections were processed for each animal. With the data obtained, mean 
values were calculated for both sections for the whole striatum. With these data, 
neuronal survival, capillary density, astrogliosis, leukocyte infiltration and microglial 
activation were determined. In case of GFAP stainings, the overall area of scar tissue 
was outlined using the Soft imaging System Olympus Cell F Program. Stereometric 
assessments of the degree of post-ischemic atrophy of the striatum and corpus 
callosum were done using modified Bielschowsky’s silver stainings as previously 
described (Ding et al., 2008). 
 
Immunohistochemistry for CB and BDA 
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Brain sections of animals that had transcardially been perfused with PFA were rinsed 
three times for 10 min each in 50 mM Tris-buffered saline (pH 8.0) containing 0.5% 
Triton X-100 (TBS-Tx). For detection of CB, sections were immersed overnight at 
4°C with polyclonal rabbit anti-Cascade Blue antibody (A-5760; Molecular Probes, 
1:100), diluted 1:100 in 50 mM TBS-Tx, followed by incubation for one hour at room 
temperature with a horseradish peroxidase (HRP)-labelled secondary anti-rabbit 
antibody (1:1000). For detection of BDA, sections were incubated overnight with 
avidin-biotin-peroxidase complex (ABC Elite; Vector Laboratories, Burlingame, CA, 
USA). Stainings were revealed with DAB containing 0.4% ammonium sulphate and 
0.004% H2O2. 
 
Analysis of corticorubral and corticobulbar projections  
The location of tracer deposits was checked at the levels of the needle tracks, thus 
ensuring that the motor cortex had indeed been injected in all animals. To account for 
variabilities in tracer uptake in different mice, we first evaluated the number of tracer-
stained fibres in the corticospinal tract (CST) both at the level of the red nucleus and 
facial nucleus. For this purpose, two consecutive sections were analysed, counting 
the number of fibres crossing the sections in four regions of interest of 2865 µm² 
each that had been selected in the dorsolateral, ventrolateral, dorsomedial and 
ventromedial portion of the CST. By measuring the total area of the CST using the 
Cell Software image system (Olympus) connected to an Olympus BX42 microscope, 
we calculated the overall number of labelled pyramidal tract fibres, as described 
(Z’Graggen et. al., 1998). 
Analysis of corticorubral projections. Corticorubral projections were evaluated at the 
level of the parvocellular red nucleus (bregma –3.0 to –3.5 mm). A 500 µm long 
intersection line was superimposed on the brain midline. Along that line those fibres 
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crossing into the contralateral hemisphere in direction of the red nucleus were 
quantified. For each animal, the total number of fibres counted was normalized with 
the total number of labelled fibres in the CST and multiplied by 100, resulting in 
percent values of fibres crossing the midline. For both tracers two consecutive 
sections were analysed. For both sections, mean values of labelled fibres were 
determined. 
Analysis of corticobulbar projections. Corticobulbar projections were assessed at the 
level of the facial nucleus (bregma –5.8 to –6.3 mm). Two 500 µm long intersection 
lines were superimposed on the sections parallel to the midline, both representing 
tangents touching the most lateral extension of the pyramidal tract. Along both lines 
those fibres crossing the lines in direction of the contralateral and ipsilateral facial 
nucleus were quantified. For each animal, the total number of fibres counted was 
normalized with the number of labelled fibres in the CST and multiplied by 100, 
resulting in percent values of fibres originating from the pyramidal tract. For both 
tracers two consecutive sections were evaluated, for which mean values of labelled 
fibres were calculated. 
 
Gene expression analysis by RT-PCR 
For gene expression studies, mice were sacrificed at three different time-points, 
namely at 3, 14 and 30 days after stroke by transcardiac perfusion with cold sterile 
0.1 M PBS containing 0.01 M EDTA (pH 7.4). Brains were immediately removed and 
dissected on dry-ice. Blocks of tissue were cut from 2 mm rostral to 2 mm caudal to 
the bregma. From these blocks, samples were collected from six regions of interest: 
the motor cortex, the striatum and the parietal cortex both ipsilateral and contralateral 
to the stroke. All regions were processed in RNA-later RNA stabilization reagent 
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(#76104; Qiagen, Hilden, Germany) and stored at -80° until RNA extraction. Brain 
tissue samples were homogenized and total RNA was isolated. 
One µg of cDNA synthesized from 2 µg of total RNA was used for RT-PCR using pre-
designed TaqMan low density arrays (TLDA) as previously described (Pluchino et al., 
2008). Briefly, for each TLDA, there were eight separate loading ports that distributed 
the cDNA into a total of 48 wells, for a total of 384 different wells per card. Each well 
contains a specific primer and probe, capable of detecting one single gene. In our 
study we designed the gene cards for 46 different genes (see Supplementary Table 
1) together with two housekeeping genes, glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) and 18S ribosomal RNA. The last one is a mandatory 
control provided by the manufacturer. RT-PCR was processed with samples obtained 
from individual animals (avoiding pooling of the tissue) from each of the six regions of 
interest, each sample containing 10 µl cDNA (1 µg). 
RT-PCR was performed using Applied Biosystems 7900HT Fast-Real-Time PCR 
System. Gene cards were analysed using the threshold cycle (CT) relative 
quantification method. CT values were normalized for endogenous reference 
[∆CT=CT (target gene) - CT (GAPDH)] and compar d with a calibrator using the 
∆∆CT formula [∆∆CT= ∆CT (sample) – ∆CT (calibrator)]. In this study, we 
consistently used GAPDH as endogenous control. As calibrator sample we utilized a 
brain obtained from an untreated mouse of the same age, sex and strain. Data were 
presented using the logarithmic transformation of F.I. (fold induction) ratios between 
ischemic vehicle- and non-ischemic vehicle-treated mice (MCAO effect) and of ratios 
between ischemic Epo 10 I.U.-  and ischemic vehicle-treated mice (Epo effect). 
 
Western blot analysis 
For Western blot analysis, mice transcardially perfused with 0.9% NaCl at 3, 14 and 
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30 days after the stroke were used. From the brains, which had also been used for 
immunohistochemistry, tissue samples were harvested from the motor cortex 
ipsilateral and contralateral to the stroke immediately adjacent to the level at which 
cryostat sections were taken (0 – 2 mm caudal to bregma). Tissue samples 
belonging to the same group were pooled, homogenized, sonicated and treated with 
protease inhibitor cocktail and phosphatase inhibitor cocktail (Kilic et al., 2010). In 
these samples, protein content was evaluated using the Bradford method. Equal 
amounts of protein were were subjected to sodium dodecyl sulphate-polyacrylamide 
gel electrophoresis (SDS-PAGE), followed by protein transfer onto a polyvinylidene 
fluoride (PVDF) membranes (Bio-Rad, Hercules, CA, USA). Membranes were 
blocked in 5% non-fat milk in 50 mM Tris-buffered saline containing 0.1% Tween 
(TBS-Tw) for 1 hour at room temperature, washed in TBS-Tw and incubated over 
night with mouse monoclonal SPRR1A antibody (provided by Prof. S.M. Strittmatter, 
Yale University, CT, USA), diluted 1:1000 in TBS-Tw. The second day the 
membranes were washed and further incubated in blocking solution with peroxidase-
conjugated goat anti-mouse antibody (Santa Cruz Biotechnology, Santa Cruz, CA, 
USA) for 1 hour at room temperature. Blots were revealed using a 
chemiluminescence kit according to the manufacturer's protocol. Protein loading was 
controlled by stripping the blots and reprobing with β-actin antibody. Protein 
abundance was evaluated by analysing the intensity of the SPRR1A band using the 
Image J Program. Three different blots were analysed,and from the results obtained, 
mean values were calculated. The relative level of protein expression was normalized 
to signal intensities measured in corresponding contralateral tissue samples 
harvested 3 days after the stroke. 
 
Statistical analysis 
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Behavioural tests were analysed by means of two-way repeated measurement 
analysis of variance (ANOVA; treatment vs time) at three different time-points starting 
with 3 days post-stroke, at the time of Epo administration. For those tests in which 
significant treatment or treatment by time interaction effects were noticed (at 0.05 
level), one-way ANOVA were done for each time-point, using least significant 
differences (LSD) tests as post-hoc tests. Tract tracing data were evaluated by 
oneway ANOVA. Histochemical data, gene and protein expression studies were 
analysed by two-way ANOVA (treatment vs time). Whenever a treatment effect or 
treatment by time interaction effect was present at the 0.05 level, two-tailed t-tests 
were performed for each time-point. 
 
Results 
 
Post-acute delivery of Epo improves post-ischemic neurological recovery 
To evaluate if Epo influences neurological recovery in the post-acute stroke phase, 
mice submitted to 30 min of left-sided MCAO were intracerebroventricularly (i.c.v.) 
treated with vehicle or Epo (1 or 10 I.U./day) starting at 3 dpi. LDF measurements 
and body weight did not show any differences between groups (Fig. 2A, B). In all 
groups, LDF decreased to ~15-20% of baseline during MCAO, followed by a rapid 
restoration of blood flow after reperfusion (Fig. 2A). Except for a transient mild 
reduction in body weight at 3 dpi (< 10%) that was similarly registered in all groups, 
no abnormalities in weight development were seen (Fig. 2B). 
Neurological recovery was investigated by grip strength (Fig. 2C) and Rotarod (Fig. 
2D) tests, which assess motor force of the paretic right forelimb and motor 
coordination. Significant reductions in motor force (Fig. 2C) and coordination skills 
(Fig. 2D) were noticed in animals submitted to 30 min MCAO. In vehicle-treated 
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ischemic animals and in animals receiving Epo at the low dosage (1 I.U./day), grip 
strength and RotaRod performance remained largely unchanged over the entire 
observation period of 42 days (Fig. 2C, D). In animals treated with Epo at the higher 
dosage (10 I.U./day), on the other hand, progressive improvement of motor force and 
coordination were observed at 14 and 42 dpi (Fig. 2C, D). Elevated O maze tests did 
not detect any differences in spontaneous locomotor activity and exploration 
behaviour between groups (Fig. 2E, F). 
 
Post-acute delivery of Epo promotes peri-lesional tissue remodeling 
In order to assess whether the post-acute delivery of Epo influences the remodeling 
of ischemic brain tissue, histochemical studies were performed. 
Immunohistochemical stainings for the neuronal marker NeuN revealed slowly 
progressive degeneration in the striatum of vehicle-treated ischemic mice, reflected 
by a continuous decline of surviving neurons (Fig. 3A) and striatal atrophy (Fig. 3B) 
that developed between 14 and 52 dpi. Notably, Epo delivered at the higher dosage 
(10 I.U./day) significantly increased neuronal survival (Fig. 3A), at the same time 
preventing striatal shrinkage (Fig. 3B). The thickness of the corpus callosum was not 
changed by Epo (Fig. 3C). 
To define Epo’s impact on angiogenesis, an accompaniment of successful 
neurovascular remodeling (Hermann and Zechariah, 2010), immunohistochemical 
stainings for the endothelial marker CD31 were assessed. Focal cerebral ischemia 
was followed by an increase in the density of CD31+ striatal capillaries to ~200% of 
baseline in vehicle-treated ischemic mice that persisted over as long as 30 days after 
MCAO (Fig. 3D). Epo further increased the capillary density, which remained 
elevated until the end of the experiments, i.e. at 52 dpi (Fig. 3D). 
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To evaluate how Epo influences the astroglial responses to stroke, stainings for the 
astrocyte marker GFAP were analysed. In vehicle-treated ischemic mice, focal 
cerebral ischemia went along with reactive astrocytes that were dispersed throughout 
the middle cerebral artery territory and persisted over the observation period of 52 dpi 
(Fig. 3E). During Epo therapy, reactive astrogliosis was less pronounced (Fig. 3E). 
However, this glial-inhibitory effect disappeared after pump removal, i.e., at 52 dpi, 
when reactive astrogliosis again returned to values similar to those of vehicle-treated 
ischemic animals (Fig. 3E). 
In the most lateral portion of the striatum, a localized scar characterized by densely 
packed GFAP+ astrocytes developed beginning at 30 days, more clearly 
distinguishable at 52 dpi in vehicle-treated mice (Fig. 3F). Epo also reduced the size 
of this latter scar (Fig. 3F). 
 
Analysis of lesion-remote plasticity using anterograde tract-tracers 
Since the pyramidal tract crosses the middle cerebral artery territory, which was 
affected by ischemia, we wanted to understand how Epo influences pyramidal tract 
degeneration and plasticity both ipsilateral and contralateral to the stroke. To this 
end, we administered two dextran conjugates, CB and BDA, into both motor cortices. 
The location of injection sites revealed no relevant differences between groups. In all 
mice, the injection sites covered the more caudal forelimb area and rostral hindlimb 
area of the primary motor cortex without relevant spreading of tracer deposits into 
subcortical structures.  
To analyse whether Epo influenced the survival of CST fibres distant to the stroke 
lesion, we counted CB-labelled fibres in the cerebral peduncle both at the level of the 
red nucleus and facial nucleus. This quantification did not reveal any differences 
between vehicle- and Epo-treated mice (red nucleus level: 44,453±9,944 vs. 
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44,629±5,509 fibres / facial nucleus level: 19,188±7,383 vs. 19,943±1,592 fibres, 
respectively), thus indicating that Epo did not influence the survival of descending 
pyramidal tract axons. Similar to CB-labelled fibres in the ipsilesional pyramidal tract, 
BDA-labelled fibres in the contralesional CST did not differ between vehicle- and 
Epo-treated mice. Similar to the total number of fibres, the overall size of the 
pyramidal tract, analysed on coronal sections at the bulbar level, was not changed by 
Epo, neither ipsilesional (0.06±0.02 vs. 0.07±0.03 mm2), nor contralesional 
(0.07±0.01 vs. 0.06±0.02 mm2) to the stroke. As such, the corticospinal system was 
not affected by secondary degeneration. 
 
Epo promotes contralesional, but not ipsilesional corticorubral plasticity 
CB- and BDA-stained fibres originating from the cerebral peduncle converted 
dorsomedially at mesencephalic levels, terminating as previously described 
(Z’Graggen et al., 1998; Brown, 2007) in the parvocellular part of the ipsilateral red 
nucleus. At this level, we quantified the number of fibres crossing the midline towards 
the contralesional red nucleus. Our results revealed a moderate (though not 
significant) increase of the percentage of CB-labelled midline crossing fibres derived 
from the ipsilesional CST upon MCAO. On the other hand, the percentage of BDA-
labelled midline crossing fibres originating from the contralesional CST remained 
unchanged (Fig. 4). Importantly, Epo significantly promoted the outgrowth of midline 
crossing fibres from the contralesional CST, without influencing the plasticity of 
ipsilesional CST fibres (Fig. 4). 
 
Epo enhances contralesional, but not ipsilesional corticobulbar plasticity  
At the midpontine level, two fibre bundles originated from the CST are innervating the 
ipsilesional and contralesional facial nucleus. At this level, we counted the fibres 
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leaving the CST in direction of both facial nuclei, evaluating fibres crossing two 
intersection lines. Our data showed that focal cerebral ischemia significantly 
increased the density of fibres originating from the CB-labelled ipsilesional CST 
innervating the ipsilesional facial nucleus, without affecting the density of fibres 
derived from the BDA-labelled contralesional CST (Fig. 5). Epo significantly 
increased the sprouting of BDA-labelled contralesional CST axons to the 
contralesional facial nucleus, at the same time mildly but non-significantly (p=0.07) 
reducing facial nucleus projections derived from the CB-labelled ipsilesional CST 
(Fig. 5). 
 
Post-ischemic remodeling by Epo involves anti-inflammatory effects 
To elucidate the mechanisms underlying Epo’s restorative actions, we performed 
semi-quantitative RT-PCR-based gene expression profiling, investigating a series of 
acute and chronic inflammation markers (for complete list see Supplementary Table 
1) in the striatum (Str), motor cortex (MCx) and parietal cortex (ParCx) of both 
hemispheres. As expected, stroke robustly increased several inflammation markers 
in the ischemic hemisphere, among which there are interleukin (IL)-1β, tumour 
necrosis factor (TNF)-α, leukemia-inhibitory factor (LIF), transforming growth factor 
(TGF)-β, IL-6, GFAP and inducible NO synthase (iNOS) (Fig. 6). Epo significantly 
reduced all these mRNAs in the ipsilesional, while to lesser extent in the 
contralesional brain hemisphere (Fig. 6). 
To further explore the immune changes induced by Epo, we performed a scatter plot 
analysis, in which we correlated in a pooled way fold induction (F.I.) values from all 
ischemic respectively non-ischemic regions for all inflammatory genes both at 14 and 
30 dpi (Supplementary Figure 1). Regression studies showed that the slope of the 
curve correlating F.I. values from Epo-treated with vehicle-treated animals was below 
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1 in both hemispheres (between 0.37 and 0.6; Supplementary Figure 1), furthermore 
supporting the observation that Epo exerts anti-inflammatory actions both ipsilaterally 
and contralaterally to ischemic stroke.  
In order to identify immune cells involved for the anti-inflammatory action of Epo, 
immunostainings for the leukocyte marker CD45 and microglia marker Iba1 were 
performed. Epo significantly reduced the brain infiltration of CD45+ leukocytes (Fig. 
3G), but not the presence of Iba1+ microglia (Fig. 3H) in the ischemic striatum. In the 
contralesional hemisphere, neither Iba1+ microglia, nor CD45+ leukocytes were 
seen. These data indicate that attenuation of leukocyte recruitment, besides reduced 
reactive astrogliosis, may contribute to Epo’s anti-inflammatory actions. 
 
Modulation of pro-plasticity and anti-plasticity markers by Epo  
To better understand how Epo influences brain plasticity both ipsilateral and 
contralateral to the stroke, additional RT-PCR studies were performed, using 
plasticity-promoting and -inhibitory genes that were previously described to be 
induced in the first days to weeks after stroke (Carmichael and Li, 2006; 
Supplementary Table 1). Induction of ischemia was accompanied by a robust 
upregulation of the mRNAs of the pro-plasticity genes small proline-rich protein 
(SPRR)1, insulin-like growth factor (IGF)-1, brain-derived neurotrophic factor (BDNF), 
vascular endothelial growth factor receptor-2 (KDR) and myristoylated alanine-rich C-
kinase substrate (MARCKS) in the ischemic but not the contralesional hemisphere 
between 3 and 30 dpi (Fig. 7). On the other hand, no comparably unequivocal pattern 
in the regulation of anti-plasticity mRNAs was observed (Fig. 7). Whereas Epo 
diminished the expression of different pro-plasticity genes (i.e., SPRR1, IGF-1 and 
KDR) in the ischemic hemisphere at 14 but not 30 dpi, Epo downregulated the anti-
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plasticity mRNAs neurocan and ephrin B1 and upregulated the pro-plasticity SPRR1 
mRNA in the non-ischemic hemisphere at 14 and 30 dpi (Fig. 7). 
To further explore plasticity-modulating actions of Epo in the stroke brain, we again 
correlated F.I. values of Epo- and vehicle-treated animals in scatter plots 
(Supplementary Figures 2 and 3). Regression studies revealed that the slope of the 
curve correlating F.I. values from Epo-treated with vehicle-treated animals was below 
1 for pro-plasticity and anti-plasticity mRNAs in both hemispheres at 14 dpi (between 
0.50 and 0.79; Supplementary Figure 2 and 3). This slope remained low for anti-
plasticity genes at 30 dpi (0.52-0.70), whereas the slope of pro-plasticity genes 
increased at the same time-point contralateral to the stroke (to 1.18). These 
observations support our finding of a plasticity-promoting effect of Epo in the 
contralesional hemisphere at the latter time-point, 30dpi. 
To evaluate whether the expression of plasticity-related mRNAs also translates into 
proteins, we prepared Western blots for the pro-plasticity protein SPRR1A using 
tissue samples obtained from the motor cortex. These blots revealed that, while 
SPRR1A expression was low in the contralesional motor cortex both in vehicle- and 
Epo-treated animals (not shown), SPRR1A was abundant after ischemia in the 
ipsilesional motor cortex (Fig. 8). In line with reduced SPRR1 mRNA levels, Epo 
markedly diminished the expression of SPRR1 protein at 14 and 30 dpi (Fig. 8). Our 
data suggest that brain plasticity is actively inhibited by Epo in the ischemic 
hemisphere. 
 
Discussion 
Using a comprehensive analysis of (i) motor and coordination deficits, (ii) 
reorganization processes of the peri-ischemic tissue, and (iii) pyramidal tract plasticity 
both ipsilateral and contralateral to the stroke, we herein show that post-acute 
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delivery of recombinant human Epo initiated as late as 72 hours after focal cerebral 
ischemia promotes functional neurological recovery in mice submitted to transient 
intraluminal MCAO by mechanisms involving perilesional tissue remodeling and 
promotion of contralateral pyramidal tract plasticity. We used an experimental 
delivery protocol, in which Epo was administered into the lateral ventricle from 3 to 30 
dpi via miniosmotic pumps. In addition to tract-tracing studies, we performed a 
detailed analysis of histochemical and molecular biological changes induced by Epo, 
showing that the growth factor inhibits inflammatory responses of the brain tissue and 
at the same time modulates plasticity genes. 
That Epo promotes neurological recovery beyond the acute stroke phase is 
noteworthy, and it opens new perspectives for post-acute therapies. In contrast to 
acute neuroprotection, which aims at preserving ischemic neurons from apoptotic or 
necrotic injury and which in case of existing studies can hardly be expected beyond a 
time-window of 3 to 6 hours after the stroke (Minnerup et al., 2009), post-acute 
therapies aim at the reorganization of the brain, both in the vicinity (Cramer and 
Chopp, 2000) and areas remote (Wiessner et al., 2003) to the stroke lesion. Slowly 
progressive secondary degeneration takes place in the striatum of vehicle-treated 
mice submitted to transient intraluminal MCAO, reflected by a continued loss of 
neurons and secondary tissue shrinkage, which in our study were both reduced by 
Epo. Our observations are in line with a previous study of our group, which reported 
secondary degeneration of the ipsilesional striatum in ischemic mice that was 
antagonized by adult neural precursor (i.e., stem) cells (Bacigaluppi et al., 2009). 
Similar to the present study, this effect was not evident in the initial recovery phase, 
but slowly developed within 2 – 4 weeks after the stroke. Inhibition of caspase-3-
dependent apoptotic cell injury was noticed in the striatum in that earlier study 
(Bacigaluppi et al., 2009), indicating that the prevention of shrinkage represented a 
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very delayed neuroprotective effect. That secondary neurodegeneration in the vicinity 
of the lesion may be relevant for stroke recovery has also been proposed by Taguchi 
et al. (2007) who reported deterioration of neurological deficits due to enhanced brain 
atrophy in granulocyte-colony stimulating factor (G-CSF)-treated mice submitted to 
distal MCAO. 
Besides preventing delayed neurodegeneration, Epo induced angiogenesis and 
inhibited reactive astrogliosis, at the same time preventing scar formation of ischemic 
tissue. Our data are in agreement with recent studies by Li et al. (2009), who have 
made MRI-based observation of peri-lesional white matter remodeling in MCAO rats 
treated with Epo within 24 hours of reperfusion. Inhibition of glial scar formation has 
previously been reported in studies evaluating cell based therapies, namely bone 
marrow-derived stem cells (Li et al., 2005) and adult neural precursor cells 
(Bacigaluppi et al., 2009), indicating that Epo shares common mechanisms of action 
with these cells. In contrast to Epo, adult neural stem/ precursor cells did not 
stimulate angiogenesis (Bacigaluppi et al., 2009). An advantage of Epo as compared 
to cell-based therapies, namely with neural precursor cells, is the lack of malignant 
tumor growth, which still remains a risk for the latter cells that cannot entirely be ruled 
out (Amariglio et al., 2009). 
In our study, induction of focal cerebral ischemia significantly increased axonal 
plasticity ipsilateral to the stroke, namely at the level of the facial nucleus. Pyramidal 
tract remodeling was recently examined by means of manganese-enhanced MRI in 
rats from 4-10 weeks after 90 min MCAO. In that study, significantly increased 
manganese transport was observed in lesion-contralateral brain structures after 
ipsilesional motor cortex injections, suggesting enhanced interhemispheric axonal 
growth (van der Zijden et al., 2008). Unlike dextran amines, manganese is a 
combined anterograde (Canals et al., 2008) and retrograde (Matsuda et al., 2010) 
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tracer, which is furthermore transsynaptically transported. Manganese therefore does 
not provide more detailed insights into plasticity processes. It has previously been 
shown however by means of histochemistry that focal cerebral ischemia induces the 
growth of short distance fibres (Carmichael et al., 2001) and promotes dendritic spine 
formation (Brown et al., 2007) in the perilesional tissue ipsilateral to the stroke. Our 
here presented data confirm that plasticity is indeed induced and that it not only 
affects short distance but also long distance projections.  
In view of the enhanced plasticity ipsilateral to the stroke, which we observed in 
vehicle-treated ischemic mice, it is noteworthy that Epo did not further enhance 
ipsilesional pyramidal tract plasticity but rather reduced it (p=0.07 at the level of the 
facial nucleus). Instead, Epo significantly increased the projections from the 
contralesional motor cortex towards the denervated red and facial nuclei. 
Contralesional sprouting was shown to correlate with functional neurological recovery 
after antagonization of the neurite growth inhibitor NogoA (Papadopoulos et al., 
2002; Wiessner et al., 2003) and bone marrow-derived stem cell therapy (Andrews et 
al., 2008). In case of neutralizing NogoA antibodies close correlations between the 
degree of functional neurological recovery and contralateral sprouting have been 
reported (Papadoupolus et al., 2002; Wiessner et al., 2003), demonstrating that 
cerebral connectivity represents a useful marker of recovery processes. Our here 
presented data confirm that stroke indeed induces plasticity in the lesioned 
hemisphere and that Epo shifts plasticity towards the contralesional hemisphere with 
a beneficial effect on functional recovery.  
In our study, Epo exhibited pronounced anti-inflammatory actions, which went along 
with a reduction of leukocyte infiltration that persisted as long as Epo was infused. It 
has already been shown that Epo and its non-erythropoietic derivatives exhibit anti-
inflammatory actions when delivered in the acute stroke phase. As such reduced 
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leukocyte infiltration (Villa et al., 2003, 2007), decreased release of TNF-α, IL-6 and 
monocyte chemoattractant protein-1 (Villa et al., 2003) and diminished expression of 
iNOS (Kilic et al., 2005a) were noticed. In cell culture, astrocytes but not leukocytes 
were shown to be responsive to Epo administration (Villa et al., 2003), suggesting 
that reduced release of inflammatory signals may be the trigger for the reduced 
invasion of blood-borne cells into the brain. By means of RT-PCR we revealed that 
Epo downregulated several pro-inflammatory genes IL-1β, TNF-α, LIF, TGF-β, IL-6, 
GFAP and iNOS, indicating that anti-inflammation may represent a mode of action, 
via which this growth factor enables brain reorganisation. Interestingly, pump removal 
in our study resulted in a rebound of leukocyte infiltration in Epo-treated mice, which 
however did not result in the reemergence of neurological deficits. Our data argue in 
favour of a critical time window, in which inflammatory responses deteriorate 
recovery processes in the ischemic brain. 
Further to this, RT-PCR-based profiling of pro-plasticity genes showed that Epo 
diminished the expression of pro-plasticity mRNAs SPRR1, IGF-1 and KDR in the 
ischemic hemisphere that were increased by the stroke. At the same time, Epo 
downregulated the anti-plasticity mRNAs neurocan and ephrin B1 and upregulated 
the pro-plasticity SPRR1 in the non-ischemic hemisphere. In case of SPRR1A, 
downregulation was also demonstrated on the protein level by means of Western 
blots. Upregulation of pro-plasticity markers in the lesion border zone has previously 
been described after permanent cortical ischemia for SPRR1, MARCKS, growth-
associated protein 43 and synaptophysin as well as delayed upregulation of anti-
plasticity markers for neurocan and ephrin B1 (Carmichael and Li, 2006; Stroemer et 
al., 1995). In our study, Epo regulated several pro- and anti-plasticity genes 
especially in the non-ischemic hemisphere at 30 days post stroke, thus providing 
evidence for a specific plasticity modulating action of this growth factor. This is in 
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accordance to previous studies on plasticity-promoting actions of Epo in rodent 
models of Parkinson’s disease (McLeod et al., 2006) and following optic nerve 
transaction (King et al., 2007). We now showed that Epo's plasticity effects are 
relevant for stroke recovery processes. 
After the German multicenter Epo trial, which has recently shown unfavourable 
effects of Epo in patients undergoing thrombolysis (Ehrenreich et al., 2009), 
presumably via exacerbation of extracellular matrix degradation by combined tissue-
plasminogen activator / Epo treatment (Zechariah et al., 2010), further 
neuroprotection studies with Epo in the acute stroke phase are rather unlikely. Our 
present study offers a basis for the prolongation of time windows far into the sub-
acute stroke phase, thus paving the way for plasticity-promoting trials with Epo, its 
non-erythropoietic derivatives (Leist et al., 2004) or with small molecule agonists of 
Epo receptors (Pankratova et al., 2010). The latter compounds, for which the utility 
for systemic delivery still has to be shown, may specifically be tailored to bind to 
Epo’s CNS receptors. Non-erythropoietic derivatives of Epo do not induce 
hematoglobin or coagulation changes, and thus do not bear an elevated risk of 
thrombembolic events, which has recently been discussed in the context of chronic 
kidney disease trials (Pfeffer et al., 2009). With these considerations, proof-of-
concept studies in human patients are promising.  
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Legends to Figures 
Fig. 1. Experimental procedures and animal groups. Mice submitted to MCAO 
that were treated with Epo or vehicle from 3 – 30 dpi were used for (A) tract tracing 
studies and behavioural analysis, (B) gene expression studies (RT-PCR) and (C) 
protein expression studies (immunohistochemistry, Western blots) and conventional 
histochemical analysis. Numbers of animals evaluated for each group and time points 
of animal sacrifice are also shown. On the far right, the rostrocaudal level, from which 
brain sections and tissue samples were harvested, is also illustrated. In addition to 
the animals shown in this scheme, additional sham-operated animals and ischemic 
animals not receiving intraventricular pumps were generated as control groups in 
some of the studies, as outlined in the Materials and Methods section. 
 
Fig. 2. Delayed delivery of Epo at 10 I.U./day, but not 1 I.U./day promotes post-
ischemic neurological recovery. (A) LDF recordings above the core of the MCA 
territory, (B) body weight, (C) grip strength of the lesion-contralateral right paretic 
forepaw, (D) coordination skills evaluated by RotaRod tests, as well as (E) locomotor 
activity and (F) exploration behaviour, assessed as number of total zone entries and 
time in open sectors in elevated O maze tests, are shown. Note that motor force (C) 
and coordination skills (D), which were compromised by the stroke, do not exhibit any 
major improvements over time in vehicle-treated mice and mice receiving Epo at a 
dosage of 1 I.U./kg, but progressively improve over 14 to 42 days in animals treated 
with Epo at a 10 I.U./kg dosage. Spontaneous locomotor activity (E) and exploration 
behaviour (F) are not influenced by Epo. LDF recordings (A) and body weight (B) do 
not differ between groups. Data are mean values ± S.D. Data were analysed by two-
way repeated measures ANOVA, followed by one-way ANOVA / LSD tests for each 
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time-point. §P< 0.05 compared with pre-ischemic baseline; *P< 0.05/ **P< 0.01 
compared with vehicle-treated ischemic mice. 
 
Fig. 3. Epo promotes peri-lesional tissue remodelling and exerts anti-
inflammatory actions. (A) Surviving neurons in ischemic striatum evaluated by 
NeuN immunohistochemistry, (B) striatal atrophy and (C) corpus callosum atrophy 
examined by Bielschowski stainings, (D) angiogenesis assessed by CD31 
immunohistochemistry, (E) diffuse astrocytosis at various time points and (F) 
circumscribed scar formation in the most lateral striatum at 52 dpi revealed by GFAP 
immunohistochemistry, as well as (G) leukocyte infiltration and (H) microglial 
activation analysed by CD45 and Iba1 immunohistochemistry. Note that Epo 
increases neuronal survival at 52 dpi (A), diminishes progressive brain atrophy (B) 
without influencing corpus callosum thickness (C), promotes angiogenesis (D), 
reduces diffuse astrocytosis (E) and glial scar formation (F) and inhibits leukocyte 
infiltration (G), without affecting microglial activation (H). Photomicrographs are also 
shown that were taken at 52 dpi (A-D,F) or 14 dpi (E,G,H). Data are mean values ± 
S.D. Data were analysed by two-way ANOVA followed by two-tailed t-tests for 
individual time points. *P< 0.05/ **P< 0.01 compared with vehicle-treated ischemic 
mice. Bar, 200 µm (B,F) /50 µm (C) /20 µm (A, D, E, G, H). 
 
Fig. 4. Epo promotes contralesional, but not ipsilesional corticorubral 
plasticity. Tract tracing analysis of corticorubral projections ipsilateral and 
contralateral to the stroke in mice receiving Cascade Blue (CB) and biotinylated 
dextran amine (BDA) injections into the lesion-sided and contralesional motor cortex 
(for placement of tracer injections see (A)). Percent of midline crossing fibres to (B) 
the contralesional red nucleus (RN) traced by CB and (C) the ipsilesional, denervated 
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RN traced by BDA. Note that the percentage of midline crossing fibres after 
ipsilesional CB injection moderately, but not significantly increases in response to 
stroke (B). Interestingly, Epo does not further elevate the percentage of midline-
crossing fibres of the ipsilesional pyramidal tract (B), but increases contralesional 
pyramidal tract sprouting across the midline resulting in fibre outgrowth towards the 
denervated lesion-sided RN (C). (D) Microphotographs of representative ischemic 
vehicle-treated and Epo-treated mice illustrating BDA traced corticorubral fibres 
intersecting the midline (superimposed in blue) in between both RN. Note that the 
denervated (left) RN receives more BDA traced fibres after Epo than after vehicle 
delivery (midline-intersecting fibres labelled with dots). Data are means ± S.D. Data 
were analysed by one way ANOVA followed by LSD tests. §P< 0.05 compared with 
vehicle-treated non-ischemic mice. *P< 0.05 compared with vehicle-treated ischemic 
mice. 
 
Fig. 5. Epo increases contralesional corticobulbar plasticity without influencing 
ipsilesional corticobulbar plasticity that is increased by the stroke. Tract tracing 
analysis of corticobulbar projections ipsilateral and contralateral to the stroke at the 
level of the facial nucleus (FN) in mice receiving CB and BDA injections into the 
ipsilesional and contralesional motor cortex (placement of tracer injections shown in 
(A)). Percent of fibres leaving the pyramidal tract in direction of the ipsilesional and 
contralesional FN traced by (B) CB and (C) BDA. Note that the percentage of fibres 
projecting to the ipsilesional FN after CB injection into the lesion-sided motor cortex 
significantly increases in response to stroke (B). Interestingly, Epo does not further 
strengthen this ipsilesional projection, but rather reduces it (B), at the same time 
increasing the percentage of BDA stained contralesional pyramidal tract fibres 
innervating the contralesional FN (C). (D) Microphotographs of representative 
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ischemic vehicle-treated and Epo-treated mice showing BDA-traced corticobulbar 
fibres crossing the intersection lines (superimposed in blue) on both sides of the 
brain. Note that Epo increases fibre outgrowth towards the contralesional FN 
(intersecting fibres labelled with dots). Data are means ± S.D. Data were analysed by 
one way ANOVA followed by LSD tests. §P< 0.05/ §§P< 0.01  compared with vehicle-
treated non-ischemic mice. *P< 0.05 compared with vehicle-treated ischemic mice. 
 
Fig. 6. Temporospatial analysis of anti-inflammatory effects of Epo in the 
lesion-sided and contralesional hemisphere. Semi-quantitative RT-PCR analysis 
summarizing the expression of inflammatory genes in the striatum (STR), motor 
cortex (MCx) and parietal cortex (ParCx) at 3, 14 and 30 dpi. Both gene expression 
changes induced by MCAO (A,B) and by Epo (C,D) are depicted. Throughout the 
time period examined, from 3 – 30 dpi, focal cerebral ischemia increased the mRNA 
levels of Il-1β, TNF-α, Lif, TGFβ, Il-6, GFAP and iNOS (A,B). Epo attenuated the 
expression of all seven genes at 14 dpi, most strongly in the ischemic hemisphere 
(C) but less pronounced also in the contralesional hemisphere (D). Data are 
logarithmic ratios of fold inductions after MCAO vs. sham surgery (A,B) and Epo vs. 
vehicle treatment (C,D). Data were analysed by two-way ANOVA. *P<0.05 compared 
with vehicle-treated ischemic mice. 
 
Fig. 7. Temporospatial analysis of plasticity-promoting and -inhibitory effects 
of Epo in the lesion-sided and contralesional hemisphere. Semi-quantitative RT-
PCR analysis summarizing the expression of pro-plasticity and anti-plasticity genes 
that were regulated by the stroke in the striatum (STR), motor cortex (MCx) and 
parietal cortex (ParCx) at 3, 14 and 30 dpi. Both gene expression changes induced 
by MCAO (A,B) and by Epo (C,D) are summarized. Throughout the time period 
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examined, focal cerebral ischemia elevated the mRNA levels of different pro-plasticity 
genes, namely of SPRR1 and IGF-1, in the ischemic hemisphere (A). Interestingly, 
Epo reduced the expression of SPRR1, IGF-1, BDNF and KDR at 14 dpi in the 
ischemic hemisphere (A), at the same time downregulating the anti-plasticity genes 
neurocan and ephrin-B1 more clearly contralateral (B) that ipsilateral (A) to the 
stroke. Data are logarithmic ratios of fold inductions after MCAO vs. sham surgery 
(A,B) and Epo vs. vehicle treatment (C,D). Data were analysed by two-way ANOVA. 
*P< 0.05 compared with vehicle-treated ischemic mice. 
 
Fig. 8. Epo downregulates SPRR1A protein in the lesion-sided motor cortex. 
Western blot analysis showing reduced abundance of SPRR1A in Epo- as compared 
with vehicle-treated mice at 14 and 30 dpi. Protein loading was controlled by 
reprobing the blots with a β-actin antibody. SPRR1A levels were densitometrically 
analysed. Data are mean values ± S.D. Data were evaluated by two-way ANOVA 
followed by two-tailed t-tests for both time points. **P< 0.01 compared with vehicle-
treated ischemic mice.  
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Legends to Supplementary Figures 
Suppl. Fig. 1. Scatter plot analysis summarizing effects of Epo on inflammatory 
markers both ipsilateral and contralateral to the stroke at 14 and 30 dpi. F.I. values 
for all inflammatory genes were pooled for all three regions of interest (ROI) both in 
the ischemic and in the non-ischemic hemisphere. Regression analysis shows that 
the slope of the curve correlating F.I. values from Epo-treated with vehicle-treated 
animals is below 1 both in the ischemic and non-ischemic hemispheres at both time 
points, indicating that Epo inhibits inflammatory responses throughout the brain. 
 
Suppl. Fig. 2. Scatter plot analysis summarizing effects of Epo on the expression of 
pro-plasticity genes both ipsilateral and contralateral to the stroke at 14 and 30 dpi. 
F.I. values for all pro-plasticity genes were pooled for all three ROI both in the 
ischemic and in the non-ischemic hemisphere. Regression analysis shows that the 
slope of the curve correlating F.I. values from Epo-treated with vehicle-treated 
animals is below 1 in both hemispheres at 14 days. At 30 dpi, the slope increases 
more strongly in the contralesional non-ischemic than ipsilesional ischemic 
hemisphere, where a slope above 1 is now noted. This observation argues in favour 
of a plasticity-promoting action of Epo in the contralesional hemisphere. 
 
Suppl. Fig. 3. Scatter plot analysis summarizing effects of Epo on the expression of 
anti-plasticity genes both ipsilateral and contralateral to the stroke at 14 and 30 dpi. 
F.I. values for all anti-plasticity genes were pooled for all three ROI both in the 
ischemic and in the non-ischemic hemisphere. Regression analysis shows that the 
slope of the curve correlating F.I. values from Epo-treated with vehicle-treated 
animals is below 1 in both hemispheres at both time points. This observation argues 
in favour of the notion that plasticity-inhibitory responses are dampened in response 
to Epo. 
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Abbreviation Gene name Assay ID 
Inflammation genes 
IL-1b interleukin-1b Mm00434228_m1 
IL-6 interleukin-6 Mm00446190_m1 
Il4 interleukin-4 Mm00445259_m1 
eNOS nitric oxide synthase 3, endothelial Mm00435204_m1 
nNOS nitric oxide synthase 1, neuronal Mm00435175_m1 
iNOS nitric oxide synthase 2 , inducible Mm00440485_m1 
IFNγ interferon-γ Mm00801778_m1 
TNFα tumor necrosis factor-α Mm00443258_m1 
LIF leukemia inhibiting factor Mm00434761_m1 
CXCR4 chemokine receptor type 4 Mm99999055_m1 
GFAP glial fibrillary acidic protein Mm00546086_m1 
TGF-β 1 transforming growth factor, beta 1 Mm03024053_m1 
MMP-9 matrix metallopeptidase 9 Mm00442991_m1 
Fgf2 fibroblast growth factor II Mm00433287_m1 
VCAM-1 vascular cell adhesion molecule-1 Mm00449197_m1 
L1cam L1 cell adhesion molecule Mm00493049_m1 
Ncam1 neural cell adhesion molecule Mm03053534_s1 
Pro-plasticity (and survival modulating) genes 
GAP43 growth associated protein 43 Mm00500404_m1 
Basp1 brain abundant, membrane attached signal protein 1 Mm02344032_s1 
MARCKS myristoylated alanine rich protein kinase C substrate Mm02524303_s1 
SPRR1 small proline-rich protein 1A Mm01962902_s1 
Ptprz1 Protein tyrosine phosphatase, receptor type z Mm00478484_m1 
CNTF ciliary neurotrophic factor Mn00446373_m1 
BDNF brain-derived neurotrophic factor Mm00432069_m1 
Cdkn1a  cyclin-dependent kinase inhibitor 1A (P21) Mm01303209_m1 
NGF neuronal growth factor Mm00443039_m1 
IGF1 insulin-like growth factor 1 Mm01233960_m1 
KDR vascular endothelial growth factor receptor 2 Mm00440111_m1 
Nrp1 neuropilin 1 Mm00435372_m1 
c-Jun c-Jun oncogene Mm00495062_s1 
Pten phosphatase and tensin homolog Mm01212532_m1 
Nefl neurofilament light peptide Mm01315666_m1 
Bmp10 bone morphogenic protein 10 Mm01963768_s1 
Caspase-3 caspase-3 Mm01195085_m1 
Anti-plasticity genes 
sema 3a semaphorin 3 a Mm00436469_m1 
Ephrin A5 Eph receptor A5 Mm00433074_m1 
Ephrin B1 Eph receptor B1 Mm00557961_m1 
Versican versican Mm00490179_m1 
Ncan neurocan Mm00484007_m1 
Ntn1  netrin1 Mm00478484_m1 
Angiogenesis genes 
VEGF-B vascular endothelial growth factor-B Mm00442102_m1 
VEGF-A vascular endothelial growth factor-A Mm00437306_m1 
ANGP1 angiopoietin Mm00456503_m1 
Epo erythropoietin  Mm01202754_g1 
Epor erythropoietin receptor Mm00833882_m1 
HIF-1α hypoxia inducible factor, α-subunit Mm00468869_m1 
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